Blood Test May Enable Early Breast Cancer Detection

A new Brazilian study offers a potential step forward in the early detection of breast cancer, a disease that remains the most common cancer among women in Brazil and a leading cause of cancer-related deaths. Researchers have developed a blood test, called RosalindTest®, that identifies molecular signals associated with the disease, potentially broadening preventative screening strategies. The test analyzes biomarkers in the bloodstream, offering a less invasive approach than current methods.

How RosalindTest® Works: Detecting Molecular Markers

RosalindTest® aims to detect breast cancer by identifying molecular markers linked to tumor development. The technology stems from research into gene expression and molecular biomarkers, seeking to translate discoveries in molecular biology into a practical clinical tool. The test analyzes circulating biomarkers in the blood, looking for signs of the disease even in its early stages. In preliminary testing, RosalindTest® demonstrated approximately 95% accuracy in distinguishing between women with and without breast cancer, according to reporting from Metrópoles.

This isn’t intended to replace existing screening methods like mammography, but rather to serve as a triage tool. A positive result would indicate the require for further investigation with established techniques. The technology was developed by LiqSci, a Brazilian biotechnology company focused on innovative diagnostics, in partnership with the Faculty of Medicine of ABC.

The Research Team and the Inspiration Behind the Name

The research was led by Glaucia Raquel Luciano da Veiga, a biomedical scientist with a doctorate in Pharmacology from the Universidade Federal de São Paulo (Unifesp), and Beatriz da Costa Aguiar Alves Reis, a geneticist holding a doctorate from the Universidade de São Paulo (USP). Dr. Veiga’s research background includes work on sympathetic nervous system activation in experimental renal failure, as detailed in her Escavador profile. Dr. Reis’s expertise lies in genetics.

The test’s name, RosalindTest®, is a tribute to Rosalind Franklin, a British scientist whose work was crucial in understanding the structure of DNA. Franklin’s contribution, particularly her “Photo 51,” was essential to the discovery of the DNA double helix, yet she did not receive the Nobel Prize awarded to James Watson and Francis Crick. Naming the test after her aims to recognize and celebrate the often-overlooked contributions of women in science.

Expanding Access to Early Detection

A key goal of RosalindTest® is to improve access to early detection, particularly in areas with limited resources. The development process included a phase involving approximately 600 women in rural areas of São Paulo and Ceará, Brazil. All laboratory analyses were conducted in partnership with the Faculdade de Medicina do ABC. The results suggest the test could be particularly valuable in regions where access to traditional screening methods is limited, potentially increasing the chances of early diagnosis and improved outcomes.

What RosalindTest® Is – and Isn’t – Designed To Do

Researchers emphasize that RosalindTest® is designed for prevention and screening, not for monitoring patients already diagnosed with breast cancer or evaluating their response to treatment. Patients undergoing treatment or with a history of breast cancer should continue to follow the protocols established by their physicians. The test focuses on identifying potential risks and prompting further investigation, rather than providing a definitive diagnosis or guiding treatment decisions.

Understanding Biomarkers and Early Cancer Detection

Biomarkers are measurable substances in the body – such as proteins, hormones, or genes – that can indicate a disease process. In the context of cancer, biomarkers can signal the presence of a tumor, its aggressiveness, or its response to therapy. The RosalindTest® specifically targets molecular markers associated with the activation of genes that promote tumor survival and growth. Detecting these markers in the bloodstream could provide an early warning sign, even before symptoms appear or abnormalities are visible on imaging scans.

The Next Steps: Clinical Validation and Wider Implementation

Although the initial results are promising, further clinical validation is essential. This will involve larger-scale studies to confirm the test’s accuracy, reliability, and effectiveness in diverse populations. Researchers will also need to assess the cost-effectiveness of RosalindTest® and develop guidelines for its implementation in clinical practice. The LiqSci company is positioned to lead these efforts, building on the foundational research and partnerships already established. The process of integrating a new diagnostic tool into routine healthcare requires careful evaluation and ongoing monitoring to ensure it delivers the intended benefits and does not introduce unintended consequences.